CardioProtect's drug trial failed, costing PharmaCorp $350M. Learn why this matters for future heart disease treatments and drug development.
·
·
4 min read
Tech stocks drove 12% S&P 500 growth in 2026. See what's behind the surge beyond AI giants and potential risks for investors.
·
·
4 min read
Will AI weapons be banned by 2026? Understand the ethical debate, human control, and developer responsibility for lethal AI at the UN.
·
·
8 min read
Novartis's Lp(a) drug failure leaves 80% undiagnosed. What went wrong, and what new treatments are on the horizon for 2026?
·
·
6 min read
73% globally lack financial tools. Can AI fix this? Learn how AI cuts inquiry times by 40% and expands credit access to 50M people.
·
·
6 min read
36 new reactors challenge IAEA oversight in 2024. Understand how the agency balances nuclear growth with safety and non-proliferation amidst budget limits.
·
·
7 min read
AI in insurance needs transparency by 2027 or client trust erodes. See why insurers must explain AI decisions for claims and underwriting.
·
·
7 min read
CoreWeave's $7.5B debt and Supermicro's surge show AI's infrastructure boom. Will gains last amid competition? Get key insights.
·
·
5 min read
Beyond nuclear power, learn how the IAEA used nuclear science to ship 1.5M insect doses, fight disease, and expand cancer treatment. Why it matters.
·
·
8 min read
Is WHO's Ebola strategy failing? Learn why community trust and local control are missing, hindering 90% vaccine uptake.
·
·
6 min read